BACKGROUND AND PURPOSE: Myeloid-related protein (Mrp) 8/14 complex is the functional relevant form of Mrp-8 and Mrp-14. Mrp-8/14 complex is actively formed in the cytoplasm of circulating neutrophils and monocytes and then secreted. Plasma Mrp-8/14 complex is emerging as a new biomarker that may discriminate between patients with an acute coronary syndrome and those with stable coronary heart disease. Little is known about the predictive value of Mrp-8/14 plaque and plasma levels for cardiovascular events after atherectomy. METHODS: Plasma and plaque Mrp-8/14 levels were determined by ELISA in 230 consecutive patients (mean age 73) who underwent carotid endarterectomy. Patients were followed for 3 years for recurrent cardiovascular events (vascular death, nonfatal vascular event, and peripheral intervention). During follow-up, 62 patients experienced an event. Baseline Mrp-8/14 levels were higher in patients who experienced an event than in event-free patients (plasma 0.78+/-0.63 versus 0.57+/-0.67 mg/L; P=0.030 and plaque 0.54+/-1.23 versus 0.08+/-1.51 mg/kg; P=0.027). In a Cox model, a 1 U increase in log Mrp-8/14 was associated with an increased risk of recurrent events (plasma, hazard ratio [HR], 1.51; 95% CI, 1.02 to 2.23, P=0.040; and plaque, HR, 1.23, 95% CI, 1.04 to 1.46, P=0.018). After multivariate adjustment for risk factors (both plasma and plaque Mrp-8/14) and plaque characteristics (only plaque Mrp-8/14), the HR remained the same for both plasma (HR, 1.50, 95% CI, 1.01 to 2.30; P=0.046) and plaque (HR, 1.20, 95% CI, 1.01 to 1.44; P=0.042). CONCLUSIONS: High Mrp-8/14 plasma and plaque levels are related to an increased risk of adverse cardiovascular events after a carotid endarterectomy, independent of traditional cardiovascular risk factors.
BACKGROUND AND PURPOSE:Myeloid-related protein (Mrp) 8/14 complex is the functional relevant form of Mrp-8 and Mrp-14. Mrp-8/14 complex is actively formed in the cytoplasm of circulating neutrophils and monocytes and then secreted. Plasma Mrp-8/14 complex is emerging as a new biomarker that may discriminate between patients with an acute coronary syndrome and those with stable coronary heart disease. Little is known about the predictive value of Mrp-8/14 plaque and plasma levels for cardiovascular events after atherectomy. METHODS: Plasma and plaque Mrp-8/14 levels were determined by ELISA in 230 consecutive patients (mean age 73) who underwent carotid endarterectomy. Patients were followed for 3 years for recurrent cardiovascular events (vascular death, nonfatal vascular event, and peripheral intervention). During follow-up, 62 patients experienced an event. Baseline Mrp-8/14 levels were higher in patients who experienced an event than in event-free patients (plasma 0.78+/-0.63 versus 0.57+/-0.67 mg/L; P=0.030 and plaque 0.54+/-1.23 versus 0.08+/-1.51 mg/kg; P=0.027). In a Cox model, a 1 U increase in log Mrp-8/14 was associated with an increased risk of recurrent events (plasma, hazard ratio [HR], 1.51; 95% CI, 1.02 to 2.23, P=0.040; and plaque, HR, 1.23, 95% CI, 1.04 to 1.46, P=0.018). After multivariate adjustment for risk factors (both plasma and plaque Mrp-8/14) and plaque characteristics (only plaque Mrp-8/14), the HR remained the same for both plasma (HR, 1.50, 95% CI, 1.01 to 2.30; P=0.046) and plaque (HR, 1.20, 95% CI, 1.01 to 1.44; P=0.042). CONCLUSIONS: High Mrp-8/14 plasma and plaque levels are related to an increased risk of adverse cardiovascular events after a carotid endarterectomy, independent of traditional cardiovascular risk factors.
Authors: Andrei Maiseyeu; Marcus A Badgeley; Thomas Kampfrath; Georgeta Mihai; Jeffrey A Deiuliis; Cuiqing Liu; Qinghua Sun; Sampath Parthasarathy; Daniel I Simon; Kevin Croce; Sanjay Rajagopalan Journal: Arterioscler Thromb Vasc Biol Date: 2012-02-02 Impact factor: 8.311
Authors: Amit N Vora; Marc P Bonaca; Christian T Ruff; Petr Jarolim; Sabina Murphy; Kevin Croce; Marc S Sabatine; Daniel I Simon; David A Morrow Journal: J Thromb Thrombolysis Date: 2012-08 Impact factor: 2.300
Authors: Sarah R Langley; Karin Willeit; Athanasios Didangelos; Ljubica Perisic Matic; Philipp Skroblin; Javier Barallobre-Barreiro; Mariette Lengquist; Gregor Rungger; Alexander Kapustin; Ludmilla Kedenko; Chris Molenaar; Ruifang Lu; Temo Barwari; Gonca Suna; Xiaoke Yin; Bernhard Iglseder; Bernhard Paulweber; Peter Willeit; Joseph Shalhoub; Gerard Pasterkamp; Alun H Davies; Claudia Monaco; Ulf Hedin; Catherine M Shanahan; Johann Willeit; Stefan Kiechl; Manuel Mayr Journal: J Clin Invest Date: 2017-03-20 Impact factor: 14.808
Authors: Jillian Johnson; Robert M Jaggers; Sreejit Gopalkrishna; Albert Dahdah; Andrew J Murphy; Nordin M J Hanssen; Prabhakara R Nagareddy Journal: Antioxid Redox Signal Date: 2021-09-10 Impact factor: 7.468
Authors: Francesca Santilli; Leonardo Paloscia; Rossella Liani; Marta Di Nicola; Massimo Di Marco; Stefano Lattanzio; Sara La Barba; Silvia Pascale; Marco Mascellanti; Giovanni Davì Journal: J Am Heart Assoc Date: 2014-07-18 Impact factor: 5.501
Authors: Terri Chiong; Esther S H Cheow; Chin C Woo; Xiao Y Lin; Lay W Khin; Chuen N Lee; Mikael Hartman; Siu K Sze; Vitaly A Sorokin Journal: Open Cardiovasc Med J Date: 2016-04-27